Stock comparison
Moderna, Inc. is 16.4x more valuable than Taysha Gene Therapies, Inc. by market capitalization ($30.38 B vs $1.85 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRNA is larger
Moderna, Inc. is 16.4x more valuable than Taysha Gene Therapies, Inc. by market capitalization ($30.38 B vs $1.85 B).
Market value leader
MRNA
Moderna, Inc. is 16.4x more valuable than Taysha Gene Therapies, Inc. by market capitalization ($30.38 B vs $1.85 B).
Revenue leader
MRNA
TSHA: $9.77M vs MRNA: $1.94B.
Profit leader
TSHA
TSHA: -$109.00M vs MRNA: -$2.82B.
Margin leader
MRNA
TSHA: -1115.3% vs MRNA: -145.2% net margin.
| Metric | TSHA | MRNA |
|---|---|---|
| Market cap | $1.85 B | $30.38 B |
| US-listed rank | #2208 | #461 |
| Revenue (latest FY) | $9.77M | $1.94B |
| Net income (latest FY) | -$109.00M | -$2.82B |
| Net margin | -1115.3% | -145.2% |
| P/E (trailing FY) | - | - |
| SEC filings | 384 | 1,447 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Moderna, Inc. is 16.4x more valuable than Taysha Gene Therapies, Inc. by market capitalization ($30.38 B vs $1.85 B).
In their latest fiscal years, Taysha Gene Therapies, Inc. reported $9.77M in revenue while Moderna, Inc. reported $1.94B.
Full pages: Taysha Gene Therapies, Inc. and Moderna, Inc., or browse the full rankings.